Hemlibra Effect Is Muted At Shire - For Now
Hemlibra has taken a bite out of Shire's FEIBA sales, but compensatory boosts in other areas of the business helped CEO Ørnskov keep the business ticking over while awaiting the finalization of Takeda's takeover.
You may also be interested in...
Approved in late August, the HAE prophylaxis drug has already yielded $51m in US revenues, with EU approval expected by year-end. The HAE franchise is a growth leader for Shire, despite peaks and valleys due to supply issues.
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.
Takeda has fleshed out several aspects of its planned acquisition of Shire, emphasizing the need for speed and decisiveness if the integration is to be successful, although investors may need more reassurance ahead of required shareholder approval.